William Blair Investment Management LLC Buys 57,332 Shares of Haemonetics Corporation $HAE

William Blair Investment Management LLC boosted its stake in shares of Haemonetics Corporation (NYSE:HAE) by 13.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 476,710 shares of the medical instruments supplier’s stock after buying an additional 57,332 shares during the quarter. William Blair Investment Management LLC owned approximately 1.02% of Haemonetics worth $23,235,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Federated Hermes Inc. grew its stake in shares of Haemonetics by 1,405.7% in the 3rd quarter. Federated Hermes Inc. now owns 46,104 shares of the medical instruments supplier’s stock valued at $2,247,000 after buying an additional 43,042 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in Haemonetics by 49.7% in the third quarter. Harbor Capital Advisors Inc. now owns 42,859 shares of the medical instruments supplier’s stock worth $2,089,000 after acquiring an additional 14,226 shares in the last quarter. Boston Partners boosted its holdings in Haemonetics by 2.2% in the second quarter. Boston Partners now owns 543,169 shares of the medical instruments supplier’s stock worth $40,660,000 after acquiring an additional 11,738 shares in the last quarter. Isthmus Partners LLC grew its stake in Haemonetics by 36.5% in the third quarter. Isthmus Partners LLC now owns 61,702 shares of the medical instruments supplier’s stock valued at $3,007,000 after acquiring an additional 16,505 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH increased its holdings in shares of Haemonetics by 36.2% during the third quarter. Fort Washington Investment Advisors Inc. OH now owns 706,312 shares of the medical instruments supplier’s stock valued at $34,426,000 after acquiring an additional 187,630 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Citigroup cut their target price on Haemonetics from $88.00 to $75.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. CJS Securities raised shares of Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. Raymond James Financial reiterated an “outperform” rating and set a $90.00 price objective on shares of Haemonetics in a report on Friday, November 14th. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Finally, Barrington Research set a $94.00 target price on shares of Haemonetics in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Haemonetics presently has a consensus rating of “Moderate Buy” and a consensus price target of $84.44.

Haemonetics Price Performance

HAE stock opened at $63.78 on Tuesday. The stock has a market cap of $2.96 billion, a PE ratio of 17.57, a P/E/G ratio of 1.32 and a beta of 0.28. The company has a 50-day moving average price of $69.80 and a 200 day moving average price of $64.27. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $87.32. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. The business had revenue of $338.97 million for the quarter, compared to the consensus estimate of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Equities research analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.